Effect of cannabinoids on neurotransmitter uptake,atpase activity and morphology of mouse brain synaptosomes

Δ¹-Tetrahydrocannabinol (Δ¹-THC) and cannabidiol (CBD), a psychoactive and a nonpsychoactive constituent of marijuana respectively, inhibit the uptake of ³H-labelled norepinephrine (NE), dopamine (DA), γ-aminobutyric acid (GABA) and serotonin (5-HT), by mouse brain synaptosomes. CBD is more effective than Δ¹-THC in the inhibition of neurotransmitter uptake. At 5 × 10^?5 M both CBD and Δ¹-THC inhibit uptake by 60–100%. The one exception to the above is the differential effect of Δ¹-THC and CBD on 5-HT uptake. At 10^?6 M of Δ¹-THC the uptake is twice that of the control value and at 5 × 10^?5 M uptake is still equal to control value. At the former concentration CBD has no effect on 5-HT uptake whereas at the latter concentration a 50 per cent inhibition is observed. Both Δ¹-THC and CBD inhibit Na⁺-K⁺-ATPase and Mg-ATPase activities; at 5 × 10^?5 M inhibition amounts to 40 per cent. Electron microscopy reveals that synaptosomal preparations are highly damaged at 5 × 10^?5 M. Thus inhibition of uptake could stem from either failure of ATPase activity, from disruption of synaptosomes, or from both.     

Role of the central autonomic nervous system in the hypotension and bradycardia induced by (-)-delta 9-trans-tetrahydrocannabinol

(-)-Δ⁹-trans-Tetrahydrocannabinol (Δ⁹-THC), when given intravenously (2 mg kg^?1) to cats, produced marked decreases in blood pressure and heart rate which developed gradually and were of prolonged duration. Cervical spinal transection (C₁-C₂) abolished these effects whereas surgical removal of neurogenic tone to the myocardium selectively eliminated the bradycardia. Bilateral vagotomy alone did not modify the action of Δ⁹-THC upon heart rate or blood pressure. Recordings of spontaneous sympathetic outflow in the inferior cardiac nerve indicated a rapid reduction in neural discharge rate after Δ⁹-THC administration. These observations support the hypothesis that Δ⁹-THC produces a cardiodecellerator and hypotensive effect by acting at some level within the sympathetic nervous system. Experiments conducted to investigate transmission in the superior cervical and stellate ganglia demonstrated that Δ⁹-THC did not alter ganglionic function. Also, responses to intravenous isoprenaline and noradrenaline were unchanged which suggested that Δ⁹-THC did not interact with α- or β- adrenoceptors. The possible action of Δ⁹-THC on central sympathetic structures was investigated by perfusion of Δ⁹-THC into the lateral cerebral ventricle. Δ⁹-THC so administered produced a significant reduction in heart rate without a substantial lowering of blood pressure. Tritiated or ¹⁴C-Δ⁹-THC perfused into the lateral ventricle demonstrated that the amount of radioactive compound passing into the peripheral circulation was insignificant and could not account for the decrease in heart rate. The current data are in agreement with the proposal that Δ⁹-THC produces cardiovascular alterations by an action on the central nervous system which results in a decrease in sympathetic tone.     

Catalepsy induced by intrastriatal injections of delta9-THC and 11-OH-delta9-THC in the rat

Intrastriatal injections of Δ⁹-THC and 1 l-hydroxy-Δ⁹-THC induced dose-dependent catalepsy in the rat, the parent compound being more potent than the metabolite. Catalepsy was not induced following intrapallidal injection of either drug. The results suggest that the caudate-putamen could be a “specific site” in the mediation of catalepsy induced by Δ⁹-THC.Intrastriatal amphetamine attenuated Δ⁹-THC-induced catalepsy whereas intrapallidal amphetamine potentiated the effect indicating a complex interaction with dopaminergic systems in the basal ganglia.Δ⁹-THC and the central cholinergic stimulant, RS-86 synergize on administration to either area indicating a possible cholinergic involvement in the phenomenon.     

Interactions of several cannabinoids with the hepatic drug metabolizing system

Spectral interactions of various cannabinoids with rat liver musomes and their effects on several musomal enzymes were studied. Δ⁹-Tetrahydrocannabinol (Δ⁹-THC), Δ⁸-tetrahydrocannabinol (Δ⁸-THC), cannabinol (CBN), and cannabidiol (CBD) produced type I spectral changes; the spectral dissociation constants K_s were 42, 37, 46 and 11·2 μM, respectively,. Aminopyrine demethylation was competitively inhibited by Δ⁸-THC, Δ⁸-THC, CBN and CBD, by the latter only in concentrations below 10 μM. The inhibitor constants were found to be 58, 60, 68 and 49 μM, respectively. In a similar way morphine demethylation was inhibited. Δ⁸-THC, however, did not inhibit this reaction, and inhibition by CBD was of mixed type at all concentrations. There was no effect of cannabinoids on aniline hydroxylation. The inhibitory potencies of cannabis constituents on drug metabolism in vitro parallel the in vivo results obtained by interaction studies with hexobarbitone. It must be concluded that CBD, which is by far more potent in inhibiting drug metabolism than other cannabinoids, contributes significantly to the effects of crude cannabis preparations at least in rodents.     

Emergence of the less common cannabinoid Δ8-Tetrahydrocannabinol in a doping sample

Δ⁸-Tetrahydrocannabinol (Δ⁸-THC) as isomer of the well-known Δ⁹-THC has a similar mode of action, and the potency was estimated to be two thirds compared with Δ⁹-THC. Content of Δ⁸-THC in plant material is low, but formulations containing Δ⁸-THC in high concentrations are gaining popularity. Δ⁸-THC is to be regarded as prohibited substance according to the Prohibited List of the World Anti-Doping Agency (WADA). Contradictory results between initial testing procedure and confirmatory quantitation for 11-Nor-9-carboxy-Δ⁹-tetrahydrocannabinol (Δ⁹-THC-COOH) of a doping control sample gave rise for follow-up testing procedures. After alkaline hydrolysis and liquid–liquid extraction, the sample was analyzed by high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) using isocratic elution instead of gradient elution, which is used for standard procedure. Isocratic elution resulted in two peaks instead of one using gradient elution. Both peaks showed same fragmentation. Using certified reference materials, one peak could be assigned to Δ⁹-THC-COOH and the other one with higher intensity to the less common 11-Nor-9-carboxy-Δ⁸-Tetrahydrocannabinol (Δ⁸-THC-COOH) in a concentration of approximately 1200 ng/ml. As complementary method, gas chromatography tandem mass spectrometry (GC-MS/MS) can also be used for identification. Here Δ⁸- and Δ⁹-THC-COOH can be distinguished by chromatography and by fragmentation. Additional investigations of doping control samples containing Δ⁹-THC-COOH revealed the simultaneous presence of Δ⁸-THC-COOH in low concentrations (0.22–8.91 ng/ml) presumably due to plant origin. Percentage of Δ⁸-THC-COOH varies from 0.05 to 2.83%. In vitro experiments using human liver microsomes showed that Δ⁸-THC is metabolized in the same way as Δ⁹-THC.     

Effects of Δ9-THC and a water soluble ester of Δ9-THC on schedule-controlled behavior

Δ⁹-Tetrahydrocannabinol (Δ⁹-THC) and one of its water soluble esters (SP-111) decreased the rates of responding by pigeons working under a variable interval 3-min schedule of food presentation, or a multiple fixed-ratio 30, fixed-interval 5-min schedule of food presentation. Δ⁹-THC was 3–6 times more potent than SP-111 and had a faster onsetof effects on behavior.     

The identification, isolation, and preservation of delta-9-tetrahydrocannabinol (delta-9-THC)

(—)-trans-Δ⁹-Tetrahydrocannabinol (Δ⁹-THC) was isolated from marihuana plant extract, by adsorptive column and glc. The adsorptive column chromatography method consisted of chromatographing marihuana extract on a column packed with a mixture of silica gel (gas chromatography grade (100/120 mesh), silver nitrate and calcium sulphate (CaSO₄·H₂O) (3:1:0·5) with benzene as the eluting solvent. The glc method consisted of chromatographing the extract on a 3 ft silanized glass column (3/8 inch o.d.) packed with 1·5 ft of 2% QF-1 and 1·5 ft of 2% OV-17 on chromosorb W, AW 30–60 mesh, prep grade. A purity of 99% for the isolated Δ⁹-THC was confirmed by infrared spectroscopy, nuclear magnetic resonance, mass spectroscopy. The effects of storage conditions on Δ⁹-THC stability, monitored by glc, indicated the best method for preserving Δ⁹-THC was at 0°, protected from light, stored under nitrogen.     

Influence of several anesthetic agents on the effects of Δ9-tetrahydrocannabinol on the heart rate and blood pressure of the mongrel dog

Δ⁹-Tetrahydrocannabinol (Δ⁹-THC) 1 mg/kg, i.v. produced a slight but significant reduction in the heart rate of conscious mongrel dogs, and these effects were greatly potentiated by pentobarbital and/or urethane anesthesia. However, significant increase in the heart rate was noted following Δ⁹-THC administration in the dogs anesthetized with a combination of morphine plus chloralose; further, neither morphine nor chloralose alone could reverse the bradycardic effects of Δ⁹-THC. Tachycardia induced by Δ⁹-THC in these dogs could be reversed by bilateral vagotomy or by pretreatment of the animals with methylatropine, or propranolol and/or practolol. The data indicated a complex interaction between Δ⁹-THC and morphine-chloralose combination and the tachycardia induced by Δ⁹-THC under this anesthesia may be due to release of epinephrine by a reflexogenic mechanism involving afferent vagi. Further, while the bradycardic effects of Δ⁹-THC were essentially identical under pentobarbital or urethane anesthesia, the hypotensive effects were similar in urethane or chloralose anesthetized dogs. The study emphasizes that anesthetic interaction should be taken into consideration while investigating mechanisms of actions of pharmacological agents.     

The distribution of delta1-tetrahydrocannabinol and 7-hydroxy-delta-tetrahydrocannabinol in the mouse brain after intraventricular injection

Δ¹-Tetrahydrocannabinol (Δ¹-THC) and 7-hydroxy-Δ¹-THC were injected into the cerebral ventricles of mice by an improved technique, and the potencies of the drugs were measured by the mouse catalepsy test. Both drugs were found to have the same activity when administered by this route as after intravenous injection. Autoradiographic experiments with tritium-labelled compounds showed that at the time of the peak behavioural effect almost all the injected dose of ³H-Δ¹-THC (1.6 mg kg^?1) or ³H-7-hydroxy-Δ¹-THC (0.6 mg kg^?1) remained in the intraventricular space and had not penetrated the brain tissue. Δ¹-THC was found to remain in the ventricles after the behavioural effect had disappeared; 3% of the injected dose was still present 2 days after injection of ³H-Δ¹-THC (1.6 mg kg^?1).     

Hypothermic effects of intraventricular and intravenous administration of cannabinoids in intact and brainstem transected cats

Δ⁹-Tetrahydrocannabinol (Δ⁹-THC, 500 μg in 40 μl), and the synthetic cannabinoid Dimethylheptylpuran (DMHP, 75 μg in 6.0 μl) were injected into ventricles III or IV of chronically implanted unanesthetized cats to determine the effect on body temperature. The hypothermia induced by administration of Δ⁹-THC into ventricle IV was faster in onset and reached a greater maximum than that induced by ventricle HI administration. Five hundred μg (i.v.) of Δ⁹-THC produced significantly less hypothermia than interventricular microinjection.Administration of Δ⁹-THC (2 mg/kg i.v.) to animals with a midcollicular transection produced significant decreases in blood pressure, heart rate, and body temperature when compared to animals receiving vehicle alone. Cats transected at C-1 were utilized to determine the rate at which body temperature was lost in animals unable to temperature regulate. Δ⁹-Tetrahydrocannabinol had no effect in these preparations indicating that direct peripheral mechanisms have little or no role in Δ⁹-THC induced hypothermia. It was further noted that Δ⁹-THC had little effect on blood pressure or heart rate in C-1 transected animals. These findings suggest a caudal brain stem site of action for the hypothermie effect of the cannabinoids.     

The effect of (minus)-delta 9-trans-tetrahydrocannibinol on myocardial contractility and venous return in anesthetized dogs

Administration of (?)-Δ⁹-trans-tetrahydrocannabinol (Δ⁹-THC, 2.5 mg/kg i.v.) to pentobarbital-anesthetized dogs in which heart rate was maintained constant by electrical pacing, decreased aortic blood pressure, cardiac output, left ventricular peak pressure and left ventricular end diastolic pressure and dP/dt. However, the contractility index (max. dP/dt)/I.P. was not altered by the compound. Furthermore, it was shown that the decrease in cardiac output due to Δ⁹-THC could be restored to original levels by an infusion of saline-dextran in quantities sufficient to elevate the left ventricular end diastolic pressure to pre-Δ⁹-THC level.In dogs in which cardiac output was maintained constant by a right heart bypass procedure Δ⁹-THC decreased blood pressure and total peripheral resistance and augmented intravascular blood volume. This increase in intravascular blood volume was significantly less (74%) in animals in which the splanchnic (superior, inferior and celiac) arteries were ligated prior to the administration of Δ⁹-THC. On the other hand, in spinal dogs Δ⁹-THC was devoid of any measurable cardiovascular effects.These observations clearly support the hypothesis that the diminution of cardiac output induced by Δ⁹-THC in animals with constant cardiac rate is primarily due to diminished venous return to the heart and not to an impaired ability of the myocardium.     

Delta 9-THC: selective impairment of corticosterone uptake by limbic structures of the rat

Δ⁹-Tetrahydrocannabinol (THC) has a marked influence on the selective uptake of ³H-corticosterone by the hippocampus and septum of the rat. Analysis of variance on blood/tissue ratios showed that a dose of 9 mg/kg of Δ⁹-THC significantly (P < 0.01) lowered ³H-corticosterone uptake in the hippocampus. Compared with uptake in frontal and hind cortices, Δ⁹-THC selectively depressed ³H-corticosterone uptake within the septum and hippocampus. The decrease in uptake across the 3 and 9 mg/kg doses for the limbic system components compared with the cortical samples is highly significant (P < 0.001) and suggests that Δ⁹-THC exerts differential actions on hormone uptake within the central nervous system.     

Δ9-tetrahydrocannabinol and its major metabolite Δ9-tetrahydrocannabinol-11-oic acid as 15-lipoxygenase inhibitors

15-Lipoxygenase (15-LOX) is one of the key enzymes responsible for the formation of oxidized low-density lipoprotein, a major causal factor for atherosclerosis. Δ(9)-Tetrahydrocannabinol (Δ(9)-THC), a major component of marijuana, has suggested to suppress atherosclerosis. Although Δ(9)-THC seems to be attractive for the prevention of atherosclerosis, there is no information about whether or not 15-LOX isoform can be inhibited by Δ(9)-THC. In the present study, Δ(9)-THC was found to be a direct inhibitor for 15-LOX with an IC(50) (50% inhibition concentration) value of 2.42 μM. Furthermore, Δ(9)-THC-11-oic acid, a major and nonpsychoactive metabolite of Δ(9) -THC, but not another Δ(9)-THC metabolite 11-OH-Δ(9)-THC (psychoactive), was revealed to inhibit 15-LOX. Taken together, it is suggested that Δ(9) -THC can abrogate atherosclerosis via direct inhibition of 15-LOX, and that Δ(9)-THC-11-oic acid is shown to be an "active metabolite" of Δ(9) -THC in this case.     

Quantitation of Δ1-tetrahydrocannabinol in plasma from cannabis smokers

A method to identify and accurately measure non-labelled Δ¹-tetrahydrocannabinol (Δ¹-THC) in blood of cannabis smokers has been developed. It consists of the following steps: To a 5 ml plasma sample is added deuterated Δ¹-THC (Δ¹-THC-d₂) as internal standard. After extraction with light petroleum and evaporation, the Δ¹-THC containing fraction is separated by chromatography on Sephadex LH-20 (1 times 40 cm) using light petroleum-chloroform-ethanol (10:10:1) as eluant. A fraction containing Δ¹-THC is collected and subjected to mass fragmentography (LKB 9000; 3% OV-17/Gas-Chrom Q; 230°). The mass spectrometer was adjusted to record the intensities of m/e 299 and 314 of Δ¹-THC and m/e 301 and 316 of Δ¹-THC-d₂. The standard curve was made by plotting peak height m/e 299/m/e 301. Peak levels of 19–26 ng ml^?1 were reached within 10 min after smoking a cigarette containing 10 mg Δ¹-THC.     

Chronic ?-tetrahydrocannabinol during adolescence increases sensitivity to subsequent cannabinoid effects in delayed nonmatch-to-position in rats

Early-onset marijuana use has been associated with short- and long-term deficits in cognitive processing. In human users, self-selection bias prevents determination of the extent to which these effects result only from drug use. This study examined the long-term effects of Δ⁹-tetrahydrocannabinol (Δ⁹-THC), the major psychoactive constituent of marijuana, in a delayed nonmatch-to-position task (DNMP). Male Long-Evans rats were injected daily with 10 mg/kg Δ⁹-THC during or after adolescence [postnatal days (PN) 21-50 or PN50-79, respectively] or with vehicle. On PN91, training in DNMP was initiated. Successful acquisition and pharmacological challenge began on approximately PN300. Decreases in accuracy were observed at lower doses of Δ⁹-THC in Δ⁹-THC-treated rats (versus vehicle-treated rats). Administration of chronic Δ⁹-THC at a younger age tended to enhance this effect. While anandamide did not decrease accuracy in any group, rats treated with Δ⁹-THC during adolescence initiated fewer trials at the 30 mg/kg dose of anandamide than did rats in the other two groups. To the extent tested, these differences were pharmacologically selective for cannabinoids, as scopolamine (positive control) decreased accuracy at the same dose in all groups and amphetamine (negative control) did not affect accuracy in any of the groups at doses that did not impair overall responding. These results suggest that repeated administration of a modest dose of Δ⁹-THC during adolescence (PN21-50) or shortly thereafter (PN50-79) produces a long-term increase in latent sensitivity to cannabinoid-induced impairment of performance in a complex operant task.     

GABAergic mediation in the inhibition of hippocampal acetylcholine turnover rate elicited by delta 9-tetrahydrocannabinol.

Both intravenous Δ⁹-tetrahydrocannabinol (Δ⁹-THC) and intraseptal muscimol reduce the turnover rate of acetylcholine (TR_ACh) in the hippocampus by 50 and 58%, respectively, without affecting the hippocampal content of ACh. The ACh content and the TR_ACh, in other areas of rat brain examined are unchanged. Bicuculline fails to alter the hippocampal TR_ACh when administered intraseptally but prevents the decreased hippocampal TR_ACh induced by Δ⁹-THC or muscimol. The effect is specific to the septal-hippocampal cholinergic pathway since lesioning the fimbria (2 hr) abolishes the effect. Moreover, neither naltrexone nor destruction of septal dopaminergic nerve terminals with 6-hydroxy-dopamine injected into area A₁₀ prevents the decreased TR_ACh after Δ⁹-THC. This suggests that neither endophinergic nor dopaminergic neurons are involved in the reduction of the TR_ACh in the hippocampas following administration of Δ⁹-THC or muscimol. When the metabolism of γ-aminobutyric acid (TR_GABA) is measured, Δ⁹-THC produces a 2-fold increase in the TR_GABA which is specific for the septum. These results suggest that Δ⁹-THC inhibits TR_ACh in the cholinergic septal-hippocampal pathway by increasing the release of GABA from septal GABAergic interneurons.     

Biliary excretion of delta1-tetrahydrocannabinol and its metabolites in the rat

Δ¹-Tetrahydrocannabinol (Δ¹-THC) administered i.v. (1 mg/kg) to anaesthetized rats with cannulated bile ducts is rapidly eliminated as metabolites in the bile. 60–70 per cent in 6 hr. In comparison with the slow excretion via faeces an extensive enterohepatic circulation, which may be of toxicological importance, is indicated.Unchanged Δ¹-THC and cannabinol are eliminated in low amounts (0.05 0.1 percent) in the bile. A few per cent consists of two or more mono-oxygenated metabolites. neither of which is identical with 7-hydroxy-Δ¹-THC or 6-β-hydroxy-Δ¹-THC. The main part of the non-conjugated metabolites is present as compounds more polar than 7-hydroxy-Δ¹-THC and as carboxylic acids. These acids were more polar than Δ¹-THC-7-oic acid which could not be identified in a free or conjugated form.In the rat about 60 per cent of the metabolites are eliminated as water-soluble conjugates. Hydrolysis with glucuronidase liberated aglycones which were mainly neutral whereas hydrolysis with alkali released neutral but also some acidic compounds. 7-Hydroxy-Δ¹-THC was identified as an aglycone of glucuronic acid and furthermore, three mono-oxygenated cannabinoids were isolated after hydrolysis and partially characterized.     

Chronic Δ<Superscript>9</Superscript>-Tetrahydrocannabinol Administration Reduces IgE<Superscript>+</Superscript>B Cells but Unlikely Enhances Pathogenic SIV<Subscript>mac251</Subscript> Infection in Male Rhesus Macaques of Chinese Origin

Delta9-tetrahydrocannabinol (Δ⁹-THC) is the major psychoactive component of the cannabis plant. Δ⁹-THC has been used in the active ingredient of Marinol as an appetite stimulant for AIDS patients. Its impact on progression of HIV-1 infection, however, remains debatable. Previous studies indicated that Δ⁹-THC administration enhanced HIV-1 infection in huPBL-SCID mice but seemingly decreased early mortality in simian immunodeficiency virus (SIV) infected male Indian-derived rhesus macaques. Here, we determine the chronic effect of Δ⁹-THC administration using 0.32 mg/kg or placebo (PBO), i.m., twice daily for 428 days on SIV_mac251 infected male Chinese-derived rhesus macaques. Sixteen animals were divided into four study groups: Δ⁹-THC⁺SIV⁺, Δ⁹-THC⁺SIV^?, PBO/SIV⁺ and PBO/SIV^? (n = 4/group). One-month after daily Δ⁹-THC or PBO administrations, macaques in groups one and three were challenged intravenously with pathogenic SIV_mac251/CNS, which was isolated from the brain of a Chinese macaque with end-staged neuroAIDS. No significant differences in peak and steady state plasma viral loads were seen between Δ⁹-THC⁺SIV⁺ and PBO/SIV⁺ macaques. Regardless of Δ⁹-THC, all infected macaques displayed significant drop of CD4/CD8 T cell ratio, loss of CD4⁺ T cells and higher persistent levels of Ki67⁺CD8⁺ T cells compared with uninfected animals. Moreover, long-term Δ⁹-THC treatment reduced significantly the frequency of circulating IgE⁺B cells. Only one Δ⁹-THC⁺SIV⁺ macaque died of simian AIDS with paralyzed limbs compared with two deaths in the PBO/SIV⁺ group during the study period. These findings indicate that chronic Δ⁹-THC administration resulted in reduction of IgE⁺B cells, yet it unlikely enhanced pathogenic SIV_mac251/CNS infection in male Rhesus macaques of Chinese origin.     

Studies on the bradycardia induced by (-)- -trans-tetrahydrocannabinol in anesthetized dogs

(?)-Δ⁹-trans-tetrahydrocannabinol (Δ⁹-THC) (39 μg-5 mg/kg, i.v.) decreased heart rate in a dose related manner in dogs under pentobarbital anesthesia. This cardiac effect of Δ⁹-THC was neither due to an impairment of transmission across the sympathetic ganglia nor to a specific stimulation of parasympathetic ganglia. Selective blockade of either parasympathetic (atropine, bilateral vagotomy) or sympathetic (propranolol, spinal section at C₂C₄ neurogenic activity to the heart partially prevented the negative chronotropic effect of Δ⁹-THC. However the bradycardic effect of Δ⁹-THC was completely abolished in animals in which the autonomic pathways to the heart were pharmacologically or surgically inactivated.Administration of Δ⁹-THC into the vascularly isolated, neurally intact cross-perfused head of dogs significantly slowed the heart rate in intact as well as debuffered recipients. This bradycardia was reduced in recipients in which the trunk was atropinized prior to cerebral administration of Δ⁹-THC into the femoral vein of the recipient in the dog cross circulation preparation also caused a significant decrease in heart rate which was essentially abolished either by bilateral vagotomy or by atropinization of the recipients.These results are compatible with the hypothesis that the negative chronotropic effects of Δ⁹-THC in dogs under pentobarbital anesthesia is of central origin and involves both a direct and reflexogenic alteration of central autonomic outflow regulating the heart rate.     

Altered regulation of glutamate release and decreased functional activity and expression of GLT1 and GLAST glutamate transporters in the hippocampus of adolescent rats perinatally exposed to Δ9-THC

The long-term effects of perinatal Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exposure – from gestational day (GD) 15 to postnatal day (PND) 9 – on hippocampal glutamatergic neurotransmission were studied in slices from the 40-day-old offspring of Δ⁹-THC exposed (Δ⁹-THC-rats) and vehicle-exposed (control) dams. Basal and in K+-evoked endogenous hippocampal glutamate outflow were both significantly decreased in Δ⁹-THC-rats. The effect of short Δ⁹-THC exposure (0.1 μM) on K⁺-evoked glutamate release disclosed a loss of the stimulatory effect of Δ⁹-THC on hippocampal glutamate release in Δ⁹-THC-rats, but not in controls. In addition, l-[³H]-glutamate uptake was significantly lower in hippocampal slices from Δ⁹-THC-rats, where a significant decrease in glutamate transporter 1 (GLT1) and glutamate/aspartate transporter (GLAST) protein was also detected. Collectively, these data demonstrate that perinatal exposure to cannabinoids induces long-term impairment in hippocampal glutamatergic neurotransmission that persist into adolescence.